(Q33745849)

29 July 2017

0 references

Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis (English)

1 reference

randomized controlled trial

29 July 2017

1 reference

primary biliary cholangitis

inferred from title

0 references

1 reference

2

G Leandro

1 reference

29 July 2017

J Goulis

1

1 reference

PubMed ID

10509495

29 July 2017

A K Burroughs

series ordinal

3

1 reference

PubMed ID

10509495

29 July 2017

language of work or name

English

0 references

publication date

1 September 1999

1 reference

29 July 2017

1 reference

29 July 2017

354

1 reference

29 July 2017

9184

1 reference

29 July 2017

1053-1060

1 reference

Primary biliary cirrhosis

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911293-X

7 January 2021

Primary biliary cirrhosis: questions and promises

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911293-X

7 January 2021

Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911293-X

7 January 2021

Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911293-X

7 January 2021

Serum bilirubin: a prognostic factor in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911293-X

7 January 2021

Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911293-X

7 January 2021

Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911293-X

7 January 2021

Quality, evolution, and clinical implications of randomized, controlled trials on the treatment of lung cancer. A lost opportunity for meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911293-X

7 January 2021

Estimators of the Mantel-Haenszel variance consistent in both sparse data and large-strata limiting models

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911293-X

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911293-X

7 January 2021

Short-term treatment of gastric ulcer. A meta-analytical evaluation of blind trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911293-X

7 January 2021

Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911293-X

7 January 2021

A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911293-X

7 January 2021

Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial. Italian Multicenter Group for the Study of UDCA in PBC

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911293-X

7 January 2021

Ursodeoxycholic acid in the treatment of primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911293-X

7 January 2021

A two year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911293-X

7 January 2021

A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911293-X

7 January 2021

Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911293-X

7 January 2021

Ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a short-term, randomized, double-blind controlled, cross-over study with long-term follow up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911293-X

7 January 2021

Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911293-X

7 January 2021

Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911293-X

7 January 2021

Prognosis in primary biliary cirrhosis: model for decision making

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911293-X

7 January 2021

Prediction of short-term survival with an application in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911293-X

7 January 2021

Surrogate end points in clinical trials: are we being misled?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911293-X

7 January 2021

Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911293-X

7 January 2021

Accuracy of staging in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911293-X

7 January 2021

Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911293-X

7 January 2021

Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911293-X

7 January 2021

Optimal timing of liver transplantation for primary biliary cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911293-X

7 January 2021

Ursodeoxycholic acid for primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2911293-X

7 January 2021

10.1016/S0140-6736(98)11293-X

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10509495